Formation and accumulation of amyloid-beta (Aβ) plaques are associated with declined memory and other neurocognitive function in Alzheimer's disease (AD) patients. However, the effects of Aβ plaques on neural progenitor cells (NPCs) and neurogenesis from NPCs remain largely unknown. The existing data on neurogenesis in AD patients and AD-like animal models remain controversial. For this reason, we utilized the nestin second-intron enhancer controlled LacZ (pNes-LacZ) reporter transgenic mice (pNes-Tg) and Bi-transgenic mice (Bi-Tg) containing both pPDGF-APP Sw,Ind and pNes-LacZ transgenes to investigate the effects of Aβ plaques on neurogenesis in the hippocampus and other brain regions of the AD-like mice. We chose transgenic mice at 2, 8 and 12 months of age, corresponding to the stages of Aβ plaque free, plaque onset and plaque progression to analyze the effects of Aβ plaques on the distribution and de novo neurogenesis of (from) NPCs. We demonstrated a slight increase in the number of NPCs in the hippocampal regions at the Aβ plaque free stage, while a significant decrease in the number of NPCs at Aβ plaque onset and progression stages. On the other hand, we showed that Aβ plaques increase neurogenesis, but not gliogenesis from post-mitotic NPCs in the hippocampus of Bi-Tg mice compared with age-matched control pNes-Tg mice. The neurogenic responses of NPCs to Aβ plaques suggest that experimental approaches to promote de novo neurogenesis may potentially improve neurocognitive function and provide an effective therapy for AD.
Introduction
Alzheimer's disease (AD) is a degenerative disorder of the brain that is characterized by senile plaques containing amyloid-beta (Aβ) aggregates and neurofibrillary tangles containing hyperphosporylated tau protein. The generation and progression of Aβ plaques in the brain are generally recognized as the principal cause of AD pathogenesis (Metsaars et al., 2003; Hayashi et al., 2004; Selkoe, 2001 ). The Aβ plaque-mediated neurotoxicity in the distinct anatomic regions of the brain including the hippocampus, frontal cortex and limbic system leads AD patients to loss of memory along with a progressive decline in other cognitive skills (Hayashi et al., 2004; Selkoe, 2001) . Despite the advancements made in understanding the cellular and molecular mechanisms associated with the neurodegeneration by Aβ plaques, effective therapy to intervene disease onset and progression and to improve neurocognitive functions in AD patients is not available at the present time. To a large extent, significant numbers of neurons died or on the way of dying at or after clinical manifestation of AD. Neuronal loss leads to neurocircuit alteration and consequently neurocognitive dysfunction. At this stage, therapy toward neuronal protection may not be effective. On the other hand, therapy aiming at neuronal regeneration may potentially delay or reverse the onset and progression of AD. Since neural stem cells and/or neural progenitors cells (NPCs) are largely present in the adult CNS, regenerative medicine aiming to improve neurocognitive function by increasing de novo neurogenesis may have great potential to the therapy of AD.
Neurogenesis has been demonstrated to contribute to maintaining normal neurological functions in animal models and has been implicated in humans (Temple, 2001; van et al., 2002; Bjorklund and Lindvall, 2000) . The persistent neurogenesis was originally thought to occur in only a few restricted areas, such as the subventricular zone (SVZ) and the subgranular zone of hippocampus (Cameron and McKay, 1998; Horner and Gage, 2002; Gage, 2002) . However, more recent studies have demonstrated the generation of new neurons in many other CNS regions, for example, the neocortex, substantia nigra and spinal cord (Rietze et al., 2000; Greenberg and Jin, 2007; Gould et al., 1999a; Lie et al., 2002; Ke et al., 2006; Chi et al., 2006) . Increasing evidence indicates that neurogenesis is critical to maintain normal neurological function, while alteration of neurogenesis is associated with neurological 
